Adding to this momentum, Kiniksa Pharmaceuticals is advancing the development of KPL-387, a fully human immunoglobulin G2 (IgG2) monoclonal antibody that targets IL-1R type 1, thereby inhibiting the activity of both IL-1α and IL-1β, key drivers of inflammation in recurrent pericarditis.58 Here, IL1A is linked to pericarditis.